6.58
price up icon4.28%   0.27
 
loading
전일 마감가:
$6.31
열려 있는:
$6.38
하루 거래량:
1.55M
Relative Volume:
1.58
시가총액:
$773.69M
수익:
-
순이익/손실:
$-174.61M
주가수익비율:
-3.3401
EPS:
-1.97
순현금흐름:
$-165.54M
1주 성능:
+4.78%
1개월 성능:
-17.13%
6개월 성능:
-21.20%
1년 성능:
-40.40%
1일 변동 폭
Value
$6.335
$6.61
1주일 범위
Value
$5.9857
$6.65
52주 변동 폭
Value
$5.9857
$16.63

89 Bio Inc Stock (ETNB) Company Profile

Name
명칭
89 Bio Inc
Name
전화
(415) 432-9270
Name
주소
142 SANSOME STREET, SAN FRANCISCO, CA
Name
직원
70
Name
트위터
Name
다음 수익 날짜
2024-12-07
Name
최신 SEC 제출 서류
Name
ETNB's Discussions on Twitter

ETNB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ETNB
89 Bio Inc
6.58 773.69M 0 -174.61M -165.54M -1.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

89 Bio Inc Stock (ETNB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-04-22 재개 BofA Securities Buy
2024-01-12 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-10-10 다운그레이드 Oppenheimer Outperform → Perform
2023-08-28 개시 UBS Buy
2023-06-13 개시 Evercore ISI Outperform
2022-05-12 업그레이드 Raymond James Outperform → Strong Buy
2021-12-20 개시 H.C. Wainwright Buy
2021-10-26 재개 Cantor Fitzgerald Overweight
2021-07-29 재개 BTIG Research Buy
2021-05-25 다운그레이드 Raymond James Strong Buy → Outperform
2021-04-21 개시 Cantor Fitzgerald Overweight
2020-10-19 개시 Raymond James Strong Buy
2020-09-25 업그레이드 BofA Securities Neutral → Buy
2020-07-31 개시 Piper Sandler Overweight
2020-07-23 개시 BTIG Research Buy
2020-07-07 개시 Chardan Capital Markets Buy
2019-12-09 개시 BofA/Merrill Neutral
2019-12-09 개시 Oppenheimer Outperform
2019-12-09 개시 RBC Capital Mkts Outperform
2019-12-09 개시 SVB Leerink Outperform
모두보기

89 Bio Inc 주식(ETNB)의 최신 뉴스

pulisher
Jan 21, 2025

89bio shares maintain Buy rating as analyst cites confidence in pegozafermin trial outcomes - MSN

Jan 21, 2025
pulisher
Jan 21, 2025

HC Wainwright Reiterates Buy Rating for 89bio (NASDAQ:ETNB) - MarketBeat

Jan 21, 2025
pulisher
Jan 20, 2025

Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - MarketBeat

Jan 20, 2025
pulisher
Jan 20, 2025

Hennion & Walsh Asset Management Inc. Takes $739,000 Position in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat

Jan 20, 2025
pulisher
Jan 20, 2025

89bio (NASDAQ: ETNB) Provides Corporate Update and Business Outlook for 2025SAN FRANCISCO, January 13, 2025 (GLOBE NEWSWIRE) – 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in innovative therapies for l - Defense World

Jan 20, 2025
pulisher
Jan 20, 2025

Weiss Ratings Reiterates “Sell (D-)” Rating for 89bio (NASDAQ:ETNB) - Defense World

Jan 20, 2025
pulisher
Jan 19, 2025

89bio, Inc. (NASDAQ:ETNB) Short Interest Up 12.2% in December - MarketBeat

Jan 19, 2025
pulisher
Jan 19, 2025

89bio (NASDAQ:ETNB) Hits New 12-Month Low After Insider Selling - Defense World

Jan 19, 2025
pulisher
Jan 18, 2025

89bio, Inc. (NASDAQ:ETNB) Insider Sells $71,149.87 in Stock - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

89bio's chief technical operations officer sells $71,149 in stock - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

89bio's chief technical operations officer sells $71,149 in stock By Investing.com - Investing.com South Africa

Jan 17, 2025
pulisher
Jan 17, 2025

89bio (NASDAQ:ETNB) Stock Price Down 4%Time to Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

89bio (NASDAQ:ETNB) Reaches New 12-Month LowTime to Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 13, 2025

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward (NASDAQ:ETNB) - Seeking Alpha

Jan 13, 2025
pulisher
Jan 13, 2025

89bio Provides Business Update and Outlook for 2025 - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

89bio Completes Phase 3 Trial Enrollment, Fortifies Position with $440M Cash Reserve - StockTitan

Jan 13, 2025
pulisher
Jan 13, 2025

89bio (NASDAQ:ETNB) Sets New 1-Year Low – Should You Sell? - Defense World

Jan 13, 2025
pulisher
Jan 12, 2025

89bio, Inc. (NASDAQ:ETNB) Shares Acquired by Barclays PLC - MarketBeat

Jan 12, 2025
pulisher
Jan 12, 2025

Barclays PLC Acquires 149,479 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Certain Warrant of 89bio, Inc. are subject to a Lock-Up Agreement Ending on 12-JAN-2025. - Marketscreener.com

Jan 11, 2025
pulisher
Jan 11, 2025

89bio (NASDAQ:ETNB) Hits New 52-Week LowHere's Why - MarketBeat

Jan 11, 2025
pulisher
Jan 11, 2025

89bio stock hits 52-week low at $6.42 amid market challenges By Investing.com - Investing.com South Africa

Jan 11, 2025
pulisher
Jan 11, 2025

89bio stock hits 52-week low at $6.42 amid market challenges - Investing.com Australia

Jan 11, 2025
pulisher
Jan 10, 2025

89bio (NASDAQ:ETNB) Stock Price Down 8.2%Here's What Happened - MarketBeat

Jan 10, 2025
pulisher
Jan 09, 2025

Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.

Jan 09, 2025
pulisher
Jan 08, 2025

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking - The Globe and Mail

Jan 08, 2025
pulisher
Jan 07, 2025

Biotech manufacturer plans to cut 120 jobs in Durham - WRAL News

Jan 07, 2025
pulisher
Jan 04, 2025

Brokerages Set 89bio, Inc. (NASDAQ:ETNB) PT at $30.33 - Defense World

Jan 04, 2025
pulisher
Jan 03, 2025

89bio's SWOT analysis: pegozafermin potential drives stock outlook By Investing.com - Investing.com Australia

Jan 03, 2025
pulisher
Jan 03, 2025

89bio (NASDAQ:ETNB) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

Jan 03, 2025
pulisher
Jan 03, 2025

89bio’s SWOT analysis: pegozafermin potential drives stock outlook By Investing.com - Investing.com Nigeria

Jan 03, 2025
pulisher
Jan 03, 2025

89bio's SWOT analysis: pegozafermin potential drives stock outlook - Investing.com India

Jan 03, 2025
pulisher
Jan 02, 2025

89bio (NASDAQ:ETNB) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat

Jan 02, 2025
pulisher
Jan 01, 2025

89bio, Inc. (NASDAQ:ETNB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 01, 2025
pulisher
Jan 01, 2025

Head to Head Review: VectivBio (NASDAQ:VECT) versus Tourmaline Bio (NASDAQ:TRML) - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

89bio (NASDAQ:ETNB) Stock Price Down 3.7%Should You Sell? - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Jane Street Group LLC Has $1.03 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World

Dec 31, 2024
pulisher
Dec 31, 2024

Jane Street Group LLC Has $1.03 Million Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat

Dec 31, 2024
pulisher
Dec 30, 2024

89bio, Inc. (NASDAQ:ETNB) Shares Purchased by Geode Capital Management LLC - Defense World

Dec 30, 2024
pulisher
Dec 30, 2024

Geode Capital Management LLC Has $15.36 Million Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat

Dec 30, 2024
pulisher
Dec 28, 2024

Barclays PLC Boosts Stock Holdings in 89bio, Inc. (NASDAQ:ETNB) - Defense World

Dec 28, 2024
pulisher
Dec 28, 2024

Barclays PLC Raises Stock Position in 89bio, Inc. (NASDAQ:ETNB) - MarketBeat

Dec 28, 2024
pulisher
Dec 25, 2024

89bio, Inc. (NASDAQ:ETNB) Holdings Reduced by Franklin Resources Inc. - MarketBeat

Dec 25, 2024
pulisher
Dec 24, 2024

89bio Grants Retention RSUs to Key Officers - Defense World

Dec 24, 2024
pulisher
Dec 23, 2024

State Street Corp Acquires 7,184 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World

Dec 23, 2024
pulisher
Dec 22, 2024

89bio (NASDAQ:ETNB) Sets New 52-Week Low – Here’s Why - Defense World

Dec 22, 2024
pulisher
Dec 20, 2024

89bio (NASDAQ:ETNB) Sets New 52-Week LowHere's Why - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

89bio stock hits 52-week low at $6.96 amid market challenges - Investing.com Canada

Dec 20, 2024

89 Bio Inc (ETNB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
자본화:     |  볼륨(24시간):